A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
University of Chicago
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
First Affiliated Hospital of Zhejiang University
Universität des Saarlandes
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Genmab
Hoffmann-La Roche
Bayer
Hoffmann-La Roche
MEI Pharma, Inc.
University of Nebraska
University of Nebraska
Genentech, Inc.
Weill Medical College of Cornell University
Hoffmann-La Roche
The First Affiliated Hospital with Nanjing Medical University
SCRI Development Innovations, LLC
Seagen Inc.
Medstar Health Research Institute
British Columbia Cancer Agency
Universität des Saarlandes
Universität des Saarlandes
German High-Grade Non-Hodgkin's Lymphoma Study Group
SWOG Cancer Research Network
Hoffmann-La Roche
M.D. Anderson Cancer Center
CTI BioPharma
Seagen Inc.
The First Affiliated Hospital with Nanjing Medical University
Hoffmann-La Roche
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Teva Branded Pharmaceutical Products R&D, Inc.
Hoffmann-La Roche
University of Southern California
Genentech, Inc.
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Fundación Leucemia y Linfoma, Spain